Altered expression of interleukin-1 receptor antagonist in different stages of mouse skin carcinogenesis

Molecular Carcinogenesis

Volumn 24, Issue 4, 1999, Pages 276-286

  La, Eunhye ^a   Muga, Stephanie J ^b   Locniskar, Mary F ^a   Fischer, Susan M ^b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Interleukin 1 ; Interleukin 1 receptor antagonist; Keratinocytes; Mouse skin

Indexed keywords

DITHRANOL; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; THAPSIGARGIN; TUMOR PROMOTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOSE RESPONSE; EPIDERMIS; FEMALE; INCUBATION TIME; KERATINOCYTE; NONHUMAN; PAPILLOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA;

EID: 0032924478     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1098-2744(199904)24:4<276::aid-mc5>3.0.co;2-%23     Document Type: Article

References (58)

1. Dinarello CA. Biologic basis for interleukin 1 in diseases. Blood 1996;87:2095-2147.
2. Dinarello CA. The interleukin 1 family: 10 years of discovery. FASEB J 1994;8:1314-1325.
3. Auron PE, Webb AC, Rosenwasser LJ, et al. Nucleotide sequence of human monocyte interleukin-1 precursor cDNA. Proc Natl Acad Sci USA 1984;81:7907-7911.
4. Ansel JC, Luger TA, Lowry D, Perry P, Roop DR, Moutz JD. The expression and modulation of IL-1α in murine keratinocytes. J Immunol 1988;140:2274-2278.
5. Sims JE, March DJ, Cosman D, et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 1988;241:585-589.
6. Colotta F, Re F, Muzio M, et al Interleukin 1 type II receptor: A decoy target for IL-1 that is regulated by IL-4. Science 1993;261:472-475.
7. Greenfeder SA, Nunes P, Kwee L, Labow M, Chizzonite RA, Ju G. Molecular cloning and characterization of a second subunit of the interleukin-1 receptor complex. J Biol Chem 1995; 270:13757-13762.
8. Eisenberg SP, Brewer MT, Verderber E, Heimdal P, Brandhuber BJ, Thompson RC. Interleukin 1 receptor antagonist is a member of the interleukin 1 gene family: Evolution of a cytokine control mechanism. Proc Natl Acad Sci USA 1991;88:5232-5236.
9. Hannum CH, Wilcox CJ, Arend WP, et al. IL-1 receptor antagonist activity of a human IL-1 inhibitor. Nature (London) 1990;343:336-340.
10. Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP. Interleukin 1 receptor antagonist binds to the 80 kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 1991; 266:10331-10336.
11. Arend WP. Interleukin 1 receptor antagonist: A new member of the interleukin 1 family. J Clin Invest 1991;88:1445-1451.
12. Haskill S, Martin G, Van Le L, et al. cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium. Proc Natl Acad Sci USA 1991; 88:3681-3685.
13. Muzio M, Polentarutti M, Sironi M, et al. Cloning and characterization of a new isoform of the interleukin 1 receptor antagonist. J Exp Med 1995;182:623-628.
14. Weissbach L, Tran K, Colquhoun SA, Champliaud MF, Towle CA. Detection of an interleukin 1 intracellular receptor antagonist mRNA variant. Biochem Biophys Res Comm 1998; 244:91-95
15. Butcher C, Steinkasserer A, Tejura S, Lennard AC. Comparison of two promoters controlling expression of secreted or intracellular IL-1 receptor antagonist. J Immunol 1994;153:701-711.
16. Phillips WG, Feldmann M, Breathnach SM, Brennan FM. Modulation of the IL-1 cytokine network in keratinocytes by intracellular IL-1α and IL-1 receptor antagonist. Clin Exp Immunol 1995;101:177-182.
17. Bigler CF, Norris DA, Weston WL, Arend WP. Interleukin 1 receptor antagonist production by human keratinocytes. J Invest Dermatol 1992;98:38-44.
18. Kutsch CL, Norris DA, Arend WP. Tumor necrosis factor α induces interleukin 1α and interleukin 1 receptor antagonist production by cultured human keratinocytes. J Invest Dermatol 1993;101:79-85.
19. Hammerberg C, Arend WP, Fisher GJ, et al. Interleukin receptor antagonist in normal and psoriatic epidermis. J Clin Invest 1992;90:571-581.
20. Shuck ME, Eessalu TE, Tracey DE, Bienkowski MJ. Cloning, heterologous expression and characterization of murine interleukin 1 receptor antagonist protein. Eur J Immunol 1991;21:2775-2780.
21. Corradi A, Franzi AT, Rubartelli A. Synthesis and secretion of interleukin 1α and interleukin 1 receptor antagonist during differentiation of cultured keratinocytes. Exp Cell Res 1995; 217:355-362.
22. Gruaz-Chatellard D, Baumberger C, Saurat JH, Dayer JM. Interleukin 1 receptor antagonist in human epidermis and cultured keratinocytes. FEBS Lett 1991;294:137-140.
23. Hirao T, Aoki H, Yoshida T, Sato Y, Kamoda H. Elevation of interleukin 1 receptor antagonist in the stratum corneum of sun-exposed and ultraviolet B-irradiated human skin. J Invest Dermatol 1996;106:1102-1107.
24. Debets R, Hegmans JP, Croughs P, et al. The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis. J Immunol 1997;158:2955-2963.
25. Stosic-Grujicic S, Lukic ML. Glucocorticoid-induced keratinocyte-derived interleukin 1 receptor antagonist. Immunol 1992; 75:293-298.
26. Casini-Raggi V, Kam L, Chong YJT, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease: A novel mechanism of chronic intestinal inflammation. J Immunol 1995;154:2434-2440.
27. Prieur AM, Kaufmann MT, Griscelli C, Dayer JM. Specific IL-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet 1987;2:1240-1242.
28. Lee WY, Butler AP, Locniskar MF, Fischer SM. Modulation of interleukin-1α mRNA expression in mouse epidermis by tumor promoters and antagonists. Mol Carcinog 1993;7:26-35.
29. Oberyszyn TM, Sabourin CLK, Bijur GN, Oberyszyn AS, Boros LG, Robertson FM. Interleukin 1α gene expression and localization of interleukin 1α protein during tumor promotion. Mol Carcinog 1993;7:238-248.
30. Yuspa SH, Harris CC. Altered differentiation of mouse epidermis cells treated with retinyl acetate in vitro. Exp Cell Res 1974;86: 95-105.
31. Morris R, Tucker K, Baldwin J, Fischer S, Slaga T. A new medium for primary cultures of adult murine epidermal cells: Application to experimental carcinogenesis. Cancer Lett 1987;34:297-304.
32. Ruggeri B, Caamano J, Goodrow T, et al. Alteration of the p53 tumor suppressor gene during mouse skin tumor progression. Cancer Res 1991;51:6615-6621.
33. Didierjean L, Salomon D, Merot Y, et al. Localization and characterization of the interleukin 1 immunoreactive pool (IL-1 alpha and beta forms) in normal human epidermis. J Invest Dermatol 1989;92:809-812.
34. Schmidt KN, Podda M, Packer L, Baeuerle PA. Anti-psoriatic drug anthralin activates transcription factor NF-κB in murine keratinocytes. J Immunol 1996;156:4514-4519.
35. Thastrup O, Linnebjerg H, Bjerrum PJ, Knudsen JB, Chrestensen SB. The inflammatory and tumor promoting sesquiterpene lactone, thapsigargin, activates platelets by selective mobilization of calcium as shown by protein phosphorylations. Biochem Biophys Acta 1987;927:65-73.
36. Fusenig NE, Breitkreutz D, Dzarlieva RT, Boukamp P, Bohnert A, Tilgen W. Growth and differentiation characteristics of transformed keratinocytes from mouse and human skin in vitro and in vivo. J Invest Dermatol 1983;81:162S-168S.
37. Conti CJ, Fries JW, Viaje A, Miller DR, Morris R, Slaga TJ. In vivo behavior of murine epidermal cell derived from initiated and noninitiated skin. Cancer Res 1988;48:435-439.
38. Ruggeri BA, Bauer B, Zhang SY, Klein-Szanto AJP. Murine squamous cell carcinoma cell lines produced by a complete carcinogenesis protocol with benzo[a]pyrene exhibit characteristic p53 mutations and the absence of H-ras and cyl 1/cyclin D1 abnormalities. Carcinogenesis 1994;15:1613-1619.
39. Grove RW, Mizutani H, Kieffer JD, Kupper TS. Inflammatory skin disease in transgenic mice that express high levels of interleukin 1α in basal epidermis. Proc Natl Acad Sci USA 1995;92:11874-11878.
40. DiGiovanni J, Decina PC, Prichett WP, Cantor J, Aalfs KK, Coombs MM. Mechanism of mouse skin tumor promotion by chrysarobin. Cancer Res 1985;45:2584-2589.
41. Kruszewski FH, Naito M, Naito Y, DiGiovanni J. Histologic alterations produced by chrysarobin (1,8-dihydroxy-3-methyl-9-anthron) in SENCAR mouse skin: Relationship to skin tumor promoting activity. J Invest Dermatol 1989;92:64-71.
42. Takemura H, Hughes AR, Thastrup O, Putney JW. Activation of calcium entry by the tumor promoter thapsigargin in parotid acinar cells. J Biol Chem 1989;264:12266-12271.
43. Blanton RA, Kupper TS, McDougall JK, Dower SK. Regulation of interleukin 1 and its receptor in human keratinocytes. Proc Natl Acad Sci USA 1992;86:1273-1277.
44. Vannier E, Dinarello CA. Histamine enhances IL-1 induced IL-1 gene expression and protein synthesis via H2 receptors in peripheral blood mononuclear cells. Comparison with IL-1 receptor antagonist. J Clin Invest 1993;92:281-287.
45. Beasley D, McGuiggin ME, Dinarello CA. Human vascular smooth muscle cells produce an intracellular form of interleukin 1 receptor antagonist. Am J Physiol 1995;269:C961-C968.
46. Kristensen M, Deleuran B, Eedy DJ, Feldmann M, Breathnach SM, Brennan FM. Distribution of interleukin 1 receptor antagonist protein (IRAP), interleukin 1 receptor, and interleukin 1 alpha in normal and psoriatic skin. Decreased expression of IRAP in psoriatic lesional epidermis. Br J Dermatol 1992; 127:305-311.
47. Watson JM, Lofquist AK, Rinehart CA, et al. The intracellular IL-1 receptor antagonist alters IL-1 inducible gene expression without blocking exogenous signaling by IL-1β. J Immunol 1995;155:4467-4475.
48. Granowitz EV, Porat R, Mier JW, et al. Hematologic and immunomodulatory effects of an interleukin 1 receptor antagonist coinfusion during low dose endotoxemia in healthy humans. Blood 1993;82:2985-2990.
49. Chirivi RGS, Garofalo A, Padura IM, Mantovani A, Giavazzi R. Interleukin 1 receptor antagonist inhibits augmentation of metastasis induced by interleukin 1 or lipopolysaccharide in a human melanoma/nude mouse system. Cancer Res 1993; 53:5051-5054.
50. 2-related mechanism in multiple myeloma. Stem Cells 1995;13(suppl 2):28-34.
51. Vidal-Vanaclocha F, Alvarez A, Asumendi A, Urcelay B, Tonino P, Dinarello CA. Interleukin 1-dependent melanoma hepatic metastasis in vivo: Increased endothelial adherence by IL-1-induced mannose receptors and growth factor production in vitro. J Natl Cancer Inst 1996;88:198-205.
52. Gruss HJ, Dolken G, Brach MA, Meitelsmann R, Herrmann F. High concentration of the IL-1 receptor antagonist in serum of patients with Hodgkin's disease. Lancet 1992;340:968.
53. Van Le L, Haskill S, Jaffe GJ, Fowler WC. Expression of interleukin-1 and interleukin-1 receptor antagonists in endometrial cancer. Gynecol Oncol 1991;42:161-164.
54. Estrov Z, Kurzrock R, Wetzler M, et al. Suppression of chronic myelogenous leukemia colony growth by IL-1 receptor antagonist and soluble IL-1 receptor: A novel application for inhibitors of IL-1 activity. Blood 1991;78:1476-1478.
55. Curtis BM, Widmer MB, De Roos P, Qwarnstrom EE. IL-1 and its receptor are translocated to the nucleus. J Immunol 1990; 144:1295-1301.
56. Grenfell S, Smithers N, Miller K, Solari R. Receptor-mediated endocytosis and nuclear transport of human IL-1α. Biochem J 1989;264:813-822.
57. Stevenson FT, Turck J, Locksley RM, Lovett DH. The N-terminal propiece of interleukin 1α is a transforming nuclear oncoprotein. Proc Natl Acad Sci USA 1997;94:508-513.
58. Burysek L, Houstek J. Multifactorial induction of gene expression and nuclear localization of mouse interleukin 1α. Cytokine 1996;8:460-467.